A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients with Unresectable Locally Advanced Pancreatic Cancer

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Smartwise Sweden AB

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Digestive System Diseases [C06], Diseases [C] - Neoplasms [C04]

Trial duration

22 Apr 2026 → ongoing

Decision date (initial)

2026-02-20

Transition trial

No

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety

To estimate the Safety of the Extroducer® Infusion Catheter System to administer drug or therapeutic solution into the peri/extravascular area of the peripheral vasculature.

Secondary objectives 6

1. To estimate the Safety of Gemcitabine Sandoz 40mg/ml once administered into the peri/extravascular area of the peripheral vasculature using the Extroducer® Infusion Catheter System.
2. To estimate the impact of the Extroducer® treatment infusions of Gemcitabine on overall survival rates.
3. To classify tumor resectability following Extroducer® treatment infusions of Gemcitabine.
4. To classify target tumor responses following Extroducer® treatment infusions of Gemcitabine.
5. To assess the subject's quality of life once treated for locally advanced pancreatic cancer.
6. To evaluate overall safety throughout the clinical investigation.

Conditions and MedDRA coding

Unresectable Locally Advanced Pancreatic Cancer

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 12

1. Able to comply with scheduled visits, treatment plan, able to undergo catheterization, imaging procedures, laboratory tests, required follow up visits, the filling out of required forms, and have the ability to understand and give written informed consent.
2. Voluntarily agrees to participate and has duly singed the Informed Consent Form.
3. Age 18 years or older.
4. Histologically confirmed, locally advanced pancreatic cancer.
5. Systemic treatment with IV chemotherapy for at least six months.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. The target tumor is a measurable tumor according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1 prior to initiating Extroducer® Gemcitabine treatment.
8. Stable disease or locally progressive disease without signs of metastatic disease as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose.
9. Locally Advanced Pancreatic Cancer not amenable to resection as evaluated at a multidisciplinary tumor board within 4 weeks prior to first dose.
10. Have acceptable organ and marrow function as defined below: i. Absolute neutrophil count (ANC) ≥ 1500 cells/mm³ (1.5x109 cells/L) ii. Hemoglobin ≥ 9.0 g/dL iii. Platelets ≥ 100,000/µL iv. Total bilirubin ≤ 2 × upper limit of normal (ULN). v. AST (Aspartate Aminotransferase) ≤ 3 × ULN. vi. ALT (Alanine Aminotransferase) ≤ 3 × ULN vii. Creatinine Within 1.5 x ULN OR Creatinine clearance ≥ 60 mL/min for patients with creatinine levels above 1.5 x ULN.
11. Women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to enrollment) must have a negative urine pregnancy test at enrollment and must agree to use a medically acceptable contraception from enrollment until final treatment of Gemcitabine.
12. Male subjects who are planning to father a child (i.e., planning a pregnancy with a partner) during the clinical investigation. i. Male subjects must agree to use highly effective contraception with female partners of childbearing potential during the clinical investigation and for 3 months after the last dose of Gemcitabine and must not donate sperm during this period. ii. Acceptable methods include: combined hormonal contraception, progestogen-only contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion in the female partner, or vasectomy of the male participant (confirmed azoospermia) plus an additional barrier method as required by local regulations. iii. Sexual abstinence is acceptable only if it is the subject’s usual and preferred lifestyle; periodic abstinence and withdrawal are not acceptable.

Exclusion criteria 11

1. Participating in another clinical investigation which may interfere with the results in this clinical investigation per investigator judgement.
2. Inability to consent.
3. Pancreatic tumor is different from adenocarcinoma (e.g., neuroendocrine, metastases). Adenosquamous is allowed.
4. Cancer has spread to other organs or non-regional lymph nodes (Metastases).
5. Unknown stage or recurrent pancreatic cancer.
6. Patient contraindication to Gemcitabine treatments.
7. Patients in which iodine contrast is contraindicated.
8. Presence of structures that impede tumor access.
9. Concurrent or prior malignancy unless disease-free for ≥3 years, with exceptions for nonmelanoma skin cancer, carcinoma in situ of the cervix or bladder, or Gleason Grade < 7 organ-confined prostate cancer. This may be subject to investigator’s judgement based on individual patient circumstances and the nature of the malignancy.
10. Unmanaged concurrent illnesses, encompassing psychiatric conditions or challenging social circumstances, that, as per the investigator's judgment, could undermine compliance to the study protocols or pose an unacceptable risk to the patient.
11. Pregnant or nursing individuals.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Occurrence of Extroducer® related Serious Adverse Events within 72 hours post Extroducer® treatment infusion with Gemcitabine.

Secondary endpoints 7

1. Occurrence of Gemcitabine related Serious Adverse Events from first Extroducer® treatment infusion with Gemcitabine until study completion.
2. Survival rates (Overall Survival (OS) and Progression Free Survival (PFS)) at 6 months after final Extroducer® treatment infusion with Gemcitabine.
3. Classification of tumor resectability according to NCCN resectability criteria before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.
4. Classification of tumor response according to RECIST before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.
5. Evaluation of the tumor marker CA-19-9 before (baseline) and after (Visits 9, 11-13) Extroducer® treatment infusion with Gemcitabine.
6. Evaluation of subjects’ quality of life using the EORTC QLQ-C30 and PANC26 questionnaires before (baseline) and after (Visits 11-13) Extroducer® treatment infusion with Gemcitabine.
7. The incidence, severity, and seriousness of Adverse Events and Device Deficiencies throughout the clinical investigation.

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Smartwise Sweden AB

Sponsor organisation

Smartwise Sweden AB

Address

P. O. Box 19

City

Tullinge

Postcode

146 21

Country

Sweden

Scientific contact point

Organisation

Smartwise Sweden AB

Contact name

Ulrik Birgersson

Public contact point

Organisation

Smartwise Sweden AB

Contact name

Ulrik Birgersson

Locations

1 EU/EEA country · 1 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 10 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

2 submissions — initial application plus substantial / non-substantial modifications